10x Genomics has launched a multi-year research partnership with Dana-Farber Cancer Institute to analyze tumor specimens from several hundred patients with major solid tumors. Employing its Chromium Flex single-cell assay alongside the Xenium spatial platform, the initiative will generate high-resolution maps of cellular composition and spatial architecture for therapies including antibody-drug conjugates, radioligand treatments, bispecific antibodies and checkpoint inhibitors. By correlating these profiles with clinical outcomes, the teams aim to identify actionable biomarkers—such as immune contexture patterns or target expression heterogeneity—that distinguish responders from non-responders. The data will inform a clinical reporting framework designed to support oncologists in selecting the most effective precision oncology regimens.

In parallel, 10x Genomics plans to build and validate a CLIA-certified laboratory to enable future diagnostic assays based on single-cell and spatial biology. The facility will provide the regulated infrastructure required for assay implementation, analytical validation and processing of clinical samples, establishing the foundation for commercial diagnostic tests. According to CEO Serge Saxonov, this lab will strengthen collaboration with both academic investigators and biopharmaceutical companies as they advance next-generation precision medicines, positioning 10x to translate deep multidimensional biology directly into patient care applications.